Valderez Ravaglio Jamur
Overview
Explore the profile of Valderez Ravaglio Jamur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jamur V, Lisboa M, Azambuja A, Brofman P
Hematol Transfus Cell Ther
. 2023 Sep;
46 Suppl 6:S393-S397.
PMID: 37704564
No abstract available.
2.
Silva I, Gomes-Junior R, da Silva E, Vaz I, Jamur V, Souza B, et al.
Hum Cell
. 2023 Aug;
36(6):2237-2246.
PMID: 37646972
Induced pluripotent stem cells (iPSCs) opened the possibility to use patient cells as a model for several diseases. iPSCs can be reprogrammed from somatic cells collected in a non-invasive way,...
3.
Rebelatto C, Boldrini-Leite L, Daga D, Marsaro D, Vaz I, Jamur V, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37629136
Mesenchymal stromal cells (MSCs) have been considered a therapeutic strategy in regenerative medicine because of their regenerative and immunomodulatory properties. The translation of MSC-based products has some challenges, such as...
4.
de Oliveira F, Jamur V, Merfort L, Pozzo A, Mai S
BMC Cancer
. 2022 Sep;
22(1):1024.
PMID: 36175852
Background: Telomere dysfunction results in aneuploidy, and ongoing chromosomal abnormalities. The three-dimensional (3D) nuclear organization of telomeres allows for a distinction between normal and tumor cells. On the other hand,...
5.
Rebelatto C, Senegaglia A, Franck C, Daga D, Shigunov P, Stimamiglio M, et al.
Stem Cell Res Ther
. 2022 Mar;
13(1):122.
PMID: 35313959
Background: COVID-19 is a multisystem disease that presents acute and persistent symptoms, the postacute sequelae (PASC). Long-term symptoms may be due to consequences from organ or tissue injury caused by...
6.
Senegaglia A, Rebelatto C, Franck C, Lima J, Boldrini-Leite L, Daga D, et al.
Cell Transplant
. 2021 Jun;
30:9636897211021008.
PMID: 34074163
The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as...
7.
Bastos F, Barussi F, Boldrini Leite L, Jamur V, Soares A, Senegaglia A, et al.
Res Vet Sci
. 2020 Aug;
132:407-415.
PMID: 32768869
This study aimed to assess the safety and reproducibility of cell therapy for its use in clinical practice. We performed immunophenotypic characterization of equine bone marrow-derived mesenchymal stromal cells (BMMSCs)...
8.
Correa A, Ottoboni G, Senegaglia A, Capriglione L, Miyague N, Boldrini Leite L, et al.
Stem Cells Int
. 2018 May;
2018:5412478.
PMID: 29760727
Pharmacological approaches are partially effective in limiting infarct size. Cell therapies using a cell population enriched with endothelial progenitor cells (EPCs) CD133 have opened new perspectives for the treatment of...